ICCC
ImmuCell Corporation
ICCC has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ICCC overall, supported by stronger fundamentals and stronger modeled upside.
ICCC Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
ICCC's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ICCC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 22x | $4.26 | -58% |
| Current | 54x | $10.22 | — |
| Fair | 83x | $15.70 | +54% |
| Expensive | 809x | $154 | +1403% |
Historical ranges are pointers, not guarantees.
ICCC's PE is 54x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ICCC in the historical PE scenario, which offers more potential upside but is not a forecast.
ICCC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect ICCC's earnings and revenue to decline, with profitability weakening.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over ICCC on the outlook, with more favorable earnings and revenue expectations.
ICCC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.19 | -34% |
| Q2 2026 | $0.07 | -68% |
| Q1 2026 | -$0.07 | -$0.03 |
| Q4 2025 | -$0.12 | +$0.14 |
| Q3 2025 | $0.29 | +$0.79 |
| Q2 2025 | $0.22 | +$0.75 |
| Q1 2025 | -$0.04 | +$0.47 |
| Q4 2024 | -$0.26 | +$0.49 |
ICCC has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ICCC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8M | +46% |
| Q2 2026 | $7.2M | +12% |
| Q1 2026 | $10.4M | +28% |
| Q4 2025 | $7.6M | -1.6% |
| Q3 2025 | $5.5M | -8.4% |
| Q2 2025 | $6.4M | +18% |
| Q1 2025 | $8.1M | +11% |
| Q4 2024 | $7.8M | +52% |
ICCC's revenue is growing: $8M last quarter, up 46% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | +12 points |
| Q2 2026 | 27% | +18 points |
| Q1 2026 | 19% | +5.2 points |
| Q4 2025 | -0.8% | -8.8 points |
| Q3 2025 | 0.4% | +9.9 points |
| Q2 2025 | 8.8% | +34 points |
| Q1 2025 | 14% | +18 points |
| Q4 2024 | 8% | +28 points |
ICCC has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ICCC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ICCC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$589.4K | +$1.2M |
| Q2 2026 | $2.3M | +58% |
| Q1 2026 | $3.4M | +173% |
| Q4 2025 | $310.2K | +$509.5K |
| Q3 2025 | -$1.8M | -$1M |
| Q2 2025 | $1.4M | +207% |
| Q1 2025 | $1.2M | +258% |
| Q4 2024 | -$199.3K | +$605.1K |
ICCC has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
ICCC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +108K shares |
| 1 year | +2.8% | +252K shares |
| 3 years | +20% | +1.6M shares |
| 5 years | +19% | +1.5M shares |
| Available history | +36% | +2.5M shares |
ICCC has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ICCC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.0x | Very low |
| Q2 2026 | -0.1x | Net Cash |
| Q1 2026 | 0.4x | Very low |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 6.5x | High |
ICCC has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ICCC on leverage, with a lower net debt burden relative to earnings.
ICCC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 34.9 | Neutral |
ICCC's weekly RSI is 56 (neutral) and its Stochastic is 35 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ICCC PE vs Healthcare Sector
| Metric | ICCC | Sector median | Relative |
|---|---|---|---|
| PE | 54x | 26x | 108% above |
| PE % | 36 | 29 | 7 pts above |
ICCC is trading at 54x earnings, a 108% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ICCC on valuation relative to its sector.
ICCC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.1 | 1.2% above |
| 20 week MA | $10.3 | 0.8% below |
| 50 week MA | $8.54 | 20% above |
| 100 week MA | $7.15 | 43% above |
| 200 week MA | $6.02 | 70% above |
ICCC's trend is mixed: it's above four of its five weekly moving averages, and 70% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ICCC on trend strength, trading above more of its moving averages.
ICCC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.90 | $6.25 | +28% |
| 2021 | $6.25 | $8.31 | +33% |
| 2022 | $8.31 | $6.23 | -25% |
| 2023 | $6.23 | $5.09 | -18% |
| 2024 | $5.09 | $4.98 | -2.2% |
| 2025 | $4.98 | $6.12 | +23% |
| 2026 YTD | $6.12 | $10.2 | +67% |
ICCC is up 67% so far in 2026, after finishing lower in three of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ICCC on returns for 2026, with the stronger performance.